{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:57:49Z","timestamp":1793447869960,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The efficacy and safety of oral semaglutide, 50 mg, in an East Asian population that also includes individuals with type 2 diabetes (T2D), who are prone to weight-related complications at lower body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) thresholds than other ethnic groups, is currently unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of once-daily oral semaglutide, 50 mg, for the treatment of overweight and obesity in East Asian individuals with or without T2D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>The OASIS 2 trial was a 68-week (plus 7 weeks of follow-up) multicenter, double-blind, placebo-controlled phase 3a randomized clinical trial conducted from November 2021 to September 2023 in Japan and South Korea. Adults with a BMI of 27.0 or greater with 2 or more related complications or a BMI of 35.0 or greater with 1 or more related complications were enrolled. Approximately 25% of participants were planned to have T2D at screening. Data were analyzed from March 2022 to July 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants were assigned 2:1 to once-daily oral semaglutide, 50 mg, or placebo, plus lifestyle recommendations, for 68 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The coprimary end points were percentage change in body weight from baseline and the proportion of participants who achieved 5% or greater body weight reductions. Changes in physical function, cardiometabolic risk factors, and safety were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 201 participants (mean [SD] age, 49 [11] years; mean [SD] body weight, 91.9 [18.2] kg; 87 [43.3%] female; 51 [25.4%] with T2D) were randomized to semaglutide (n\u2009=\u2009134) or placebo (n\u2009=\u200967). The mean (SEM) percentage change in body weight was \u221214.3% (0.8) with semaglutide vs \u22121.3% (1.1) with placebo (estimated treatment difference, \u221213.07 percentage points; 95% CI, \u221215.61 to \u221210.52;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). More participants had 5% or greater body weight reductions with semaglutide vs placebo (107 of 127 [84.3%] vs 11 of 64 [17.2%]; odds ratio, 23.00; 95% CI, 10.28-51.42;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Gastrointestinal tract adverse events were reported by 85 of 134 participants (63.4%) with semaglutide and 23 of 66 with placebo (34.8%). Adverse events led to treatment discontinuation in 6 of 134 participants (4.5%) in the semaglutide arm.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this randomized clinical trial, among East Asian adults with overweight or obesity, with or without T2D, oral semaglutide, 50 mg, led to a superior and clinically meaningful reduction in body weight compared with placebo, with a safety profile consistent with the glucagon-like peptide-1 receptor agonist class.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05132088\">NCT05132088<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.3599","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T15:01:02Z","timestamp":1754319662000},"page":"1206","source":"Crossref","is-referenced-by-count":28,"title":["Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes"],"prefix":"10.1001","volume":"185","author":[{"given":"Takashi","family":"Kadowaki","sequence":"first","affiliation":[{"name":"Toranomon Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Dam","family":"Heftdal","sequence":"additional","affiliation":[{"name":"Novo Nordisk, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Jin","family":"Ko","sequence":"additional","affiliation":[{"name":"Kyungpook National University School of Medicine, Kyungpook National University Hospital, Daegu, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Overvad","sequence":"additional","affiliation":[{"name":"Novo Nordisk, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Osaka University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha K.","family":"Thamattoor","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Kon","family":"Kim","sequence":"additional","affiliation":[{"name":"Gachon University College of Medicine, Gachon University Gil Medical Center, Incheon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"OASIS 2 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Kunishige","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Okude","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sato","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takeda","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Uemura","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Osonoi","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Isshiki","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoaki","family":"Ito","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Naito","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Oka","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Hosoya","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyoko","family":"Saito","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Takizawa","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Asano","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Shirabe","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Asakura","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Kaneshiro","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Matsuura","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akeo","family":"Ohira","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saburo","family":"Nakano","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumichi","family":"Mori","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Matsumura","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Nagasawa","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Uchida","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Kikuno","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuka","family":"Kaneko","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Onaka","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ueba","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Onda","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Minami","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Osugi","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Tokumoto","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Motohashi","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Okada","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Machida","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kizawa","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Nishizawa","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Maeda","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujishima","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Nagashima","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Horie","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Ohyama","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazu","family":"Yoshida","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaji","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kishi","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutarou","family":"Soeda","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Fujita","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Tsuji","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Yagi","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Owada","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Kanada","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Furuie","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Suga","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Inomoto","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Yoshida","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yamahara","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Nanto","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Soma","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kawai","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Kawai","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ito","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Otake","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunju","family":"Sung","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"InYoung","family":"Cho","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HyunJung","family":"Yoon","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HyunJun","family":"Kang","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Kon","family":"Kim","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Jin","family":"Ko","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Eun","family":"Hong","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Young","family":"Kim","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeyeon","family":"Koo","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Lee","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-byul","family":"Cho","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MunYoung","family":"Yoo","sequence":"additional","affiliation":[{"name":"for the OASIS 2 Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"ioi250046r3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa1010679","article-title":"Association between body-mass index and risk of death in more than 1 million Asians.","volume":"364","author":"Zheng","year":"2011","journal-title":"N Engl J Med"},{"key":"ioi250046r4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1467-789X.2007.00439.x","article-title":"Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension.","volume":"9","author":"Huxley","year":"2008","journal-title":"Obes Rev"},{"issue":"8","key":"ioi250046r5","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2337\/dc10-2300","article-title":"Deriving ethnic-specific BMI cutoff points for assessing diabetes risk.","volume":"34","author":"Chiu","year":"2011","journal-title":"Diabetes Care"},{"issue":"1","key":"ioi250046r6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/nyas.12098","article-title":"Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States.","volume":"1281","author":"Ma","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"ioi250046r7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.7570\/jomes.2018.27.3.198","article-title":"Prevalence of obesity and incidence of obesity-related comorbidities in Koreans based on National Health Insurance Service health checkup data 2006-2015 (J Obes Metab Syndr 2018;27:46-52).","volume":"27","author":"Seo","year":"2018","journal-title":"J Obes Metab Syndr"},{"issue":"1","key":"ioi250046r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7570\/jomes23016","article-title":"Evaluation and treatment of obesity and its comorbidities: 2022 update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity.","volume":"32","author":"Kim","year":"2023","journal-title":"J Obes Metab Syndr"},{"issue":"3","key":"ioi250046r9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1507\/endocrj.EJ23-0593","article-title":"Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan.","volume":"71","author":"Ogawa","year":"2024","journal-title":"Endocr J"},{"issue":"3","key":"ioi250046r10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10403","key":"ioi250046r11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"20","key":"ioi250046r12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"ioi250046r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100076","article-title":"Why does type 2 diabetes mellitus impair weight reduction in patients with obesity? a review.","volume":"7","author":"Bays","year":"2023","journal-title":"Obes Pillars"},{"issue":"7","key":"ioi250046r15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S2213-8587(21)00088-7","article-title":"Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study.","volume":"9","author":"Caleyachetty","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10403","key":"ioi250046r16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"ioi250046r17","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3945\/ajcn.112.035758","article-title":"Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk\/Intra-Abdominal Adiposity.","volume":"96","author":"Nazare","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"ioi250046r18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/sj.ijo.0803248","article-title":"Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study.","volume":"30","author":"Kadowaki","year":"2006","journal-title":"Int J Obes (Lond)"},{"issue":"9","key":"ioi250046r19","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.2337\/dc07-0218","article-title":"Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men.","volume":"30","author":"Okauchi","year":"2007","journal-title":"Diabetes Care"},{"issue":"11","key":"ioi250046r20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.5551\/jat.12963","article-title":"Reduction of visceral fat correlates with the decrease in the number of obesity-related cardiovascular risk factors in Japanese with abdominal obesity (VACATION-J study).","volume":"19","author":"Hiuge-Shimizu","year":"2012","journal-title":"J Atheroscler Thromb"},{"issue":"12","key":"ioi250046r21","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1111\/dom.15258","article-title":"Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: randomized, parallel-group, multicentre, open-label trial (COMING study).","volume":"25","author":"Kimura","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"ioi250046r22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"ioi250046r23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/01.hjr.0000170264.84820.8e","article-title":"A comparison of the associations between risk factors and cardiovascular disease in Asia and Australasia.","volume":"12","author":"Woodward","year":"2005","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"8","key":"ioi250046r24","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/ijs.12166","article-title":"A comparative analysis of risk factors and stroke risk for Asian and non-Asian men: the Asia Pacific cohort studies collaboration.","volume":"8","author":"Hyun","year":"2013","journal-title":"Int J Stroke"},{"issue":"25","key":"ioi250046r25","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1161\/CIRCULATIONAHA.108.790048","article-title":"Cardiovascular disease and risk factors in Asia: a selected review.","volume":"118","author":"Ueshima","year":"2008","journal-title":"Circulation"},{"issue":"24","key":"ioi250046r26","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"ioi250046r27","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12589","article-title":"Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: patient-reported outcomes from the STEP 6 trial.","volume":"13","author":"Kolotkin","year":"2023","journal-title":"Clin Obes"},{"issue":"2","key":"ioi250046r29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7570\/jomes21022","article-title":"2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea.","volume":"30","author":"Kim","year":"2021","journal-title":"J Obes Metab Syndr"},{"issue":"3","key":"ioi250046r31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.arcmed.2006.10.014","article-title":"High frequency of cardiovascular risk factors in overweight adult Japanese subjects.","volume":"38","author":"Yang","year":"2007","journal-title":"Arch Med Res"},{"issue":"7","key":"ioi250046r32","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/01.STR.0000169925.57251.4e","article-title":"Body mass index and mortality from cardiovascular disease among Japanese men and women: the JACC study.","volume":"36","author":"Cui","year":"2005","journal-title":"Stroke"},{"issue":"1","key":"ioi250046r33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review.","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"ioi250046r28","volume-title":"Guidelines for the Management of Obesity Disease 2022","author":"Japan Society for the Study of Obesity","year":"2022"},{"key":"ioi250046r30","volume-title":"Guidelines for the Management of Obesity Disease 2016","author":"Japan Society for the Study of Obesity","year":"2016"},{"key":"ioi250046r1","unstructured":"Asian Development Bank Institute. The imminent obesity crisis in Asia and the Pacific: first cost estimates. Accessed January 24, 2024. https:\/\/www.adb.org\/publications\/imminent-obesity-crisis-asia-and-pacific-first-cost-estimates"},{"key":"ioi250046r2","unstructured":"World Health Organization. Obesity and overweight. Accessed January 24, 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"ioi250046r13","unstructured":"European Medicines Agency. Guideline for good clinical practice E6(R2)\u2014step 5. Accessed January 24, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-good-clinical-practice-e6r2-step-5_en.pdf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2836932\/jamainternal_kadowaki_2025_oi_250046_1759395965.65814.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:01:59Z","timestamp":1759762919000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2836932"}},"subtitle":["The OASIS 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.3599","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}